Dr. Robert Huizinga reports

KANE ANNOUNCES PUBLICATION OF REAL-WORLD EVIDENCE IN THE INTERNATIONAL WOUND JOURNAL

Kane Biotech Inc. has published a clinical investigative study in the International Wound Journal evaluating revyve anti-microbial wound gel as an adjunct to clinician-directed standard wound care in patients with chronic and complex wounds.

The open-access article, "Multidimensional Wound Healing Outcomes in Chronic and Complex Wounds: A Real-World Case Series With a Thermoreversible Wound Gel," reports findings from a prospective observational case series involving 17 adults and 28 chronic wounds treated in a real-world outpatient setting for up to 12 weeks. The article's lead author was Dr. Iris Noland from the Colborne Clinic, along with authors from Kane. Wound types included venous leg ulcers, diabetic foot ulcers, pressure ulcers, surgical site complications and traumatic wounds. Chronic wounds are wounds that fail to heal within an expected time frame, typically about four weeks, and complex wounds are often slowed by factors such as infection, biofilms, poor circulation or underlying conditions such as diabetes. revyve anti-microbial wound gel was used as an adjunct to clinician-directed standard of care.

Key messages from the study:

• Real-world evidence in chronic wounds: The case series evaluated 17 patients with 28 chronic and complex wounds. The median wound duration before treatment was 22 months, and all wounds had previously failed prior wound care treatment without achieving closure.
• Wound area reduction: Mean percentage area reduction (PAR) was 43.9 per cent at the wound level and 42.7 per cent at the patient level over 12 weeks.
• Wound bed improvement: The proportion of wounds demonstrating epithelial tissue increased from 25.0 per cent to 68.8 per cent while wounds exhibiting necrotic tissue decreased from 25.0 per cent to 12.5 per cent.
• Improved exudate management: The proportion of wounds classified as having low exudate (the fluid that drains from a wound, which can delay healing when excessive) increased from 41.2 per cent at baseline to 64.7 per cent at final assessment.
• Meaningful pain reduction: Mean patient-reported pain scores decreased from 4.76 to 2.18 on a 10-point scale (a baseline score of 4.76 represents moderate pain that can meaningfully affect daily life), an approximately 54.4-per-cent reduction based on group-level means, with a statistically significant within-patient improvement.
• Tissue oxygenation and healing: In patients with available imaging data, increased tissue oxygenation was positively correlated with percentage area reduction.

The authors concluded that adjunctive use of revyve was associated with improvements in wound area reduction, wound bed characteristics, exudate burden and patient-reported pain. The study also found that exploratory tissue oxygenation results were directionally consistent with clinical healing outcomes. The authors noted that the findings support further evaluation of the gel in larger, controlled studies.

"This peer-reviewed publication adds important real-world evidence to the growing body of research supporting revyve technology," said Dr. Robert Huizinga, interim chief executive officer of Kane Biotech. "The study evaluated high-risk patients with long-standing, difficult-to-heal wounds who had failed prior therapy and reported improvement across several clinically relevant measures. These findings reinforce the potential role of revyve in wound care treatment."

About Kane Biotech Inc.

Kane Biotech is commercializing and developing novel wound care treatments that disrupt biofilms and transform healing outcomes. Biofilms are one of the main contributors to antibiotic resistance in wounds, resulting in serious clinical outcomes and significant cost. revyve addresses both biofilms and wound bacteria. revyve anti-microbial wound gel, revyve anti-microbial wound gel spray and revyve anti-microbial skin and wound cleanser are all U.S. FDA 510(k) cleared. revyve anti-microbial wound gel and revyve anti-microbial wound gel spray are also Health Canada licensed.

We seek Safe Harbor.